Adverum Biotechnologies

May 03, 2021

Adverum Biotechnologies Explains Phase 2 Trial of ADVM-022

Following a significant adverse event in which a patient lost vision in an eye treated with ADVM-022, Adverum Biotechnologies has unveiled the details of its Phase 2 trial of this gene therapy for diabetic macular edema. An overgrowth of blood vessels Wet age-related macular degeneration (AMD) is caused when blood vessels from underneath the retina...

Removing Senescent Cells Improves the Brains of Female Mice
Researchers publishing in Nature Communications have detailed how the removal of p16-producing senescent cells leads to improvements in the brains of female mice [1]. Disease-associated microglia and senescence […]
Short-Term Rapamycin Treatment Extends Lifespan in Flies
Journal Club returns live on our Facebook channel on October 25th at 12:00 Eastern time. Dr. Oliver Medvedik will be taking a look at a recent study […]
Coffee Is Associated with Better Cardiovascular Health
Drawing on data from UK Biobank, scientists have once again confirmed the association between coffee and better health outcomes, with […]

Healthy Habits to Lose Weight More Quickly
Maintaining a healthy weight is important for health, especially with advancing age. Here are some ways to improve your chances of losing weight and […]
Is Aging Inevitable?
Many people dread the thought of getting old, not because having more miles on the clock is something to be ashamed of, but because of the fear of the age-related diseases that accompany those added […]
What is Aging? The Nine Reasons We Age
It’s strange how much people talk about aging but do so without really understanding what it is. Aches and pains, loss of energy, and […]

Menu

Tag: Adverum Biotechnologies

Adverum Biotechnologies Explains Phase 2 Trial of ADVM-022

Stay in the know